ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 080

Expansion of Type I IFN-driven ISGhigh Monocytes and Identification of MAS-Associated CD8+ T cell Population During Macrophage Activation Syndrome

Susan Canny1, Hannah DeBerg2, Gessay Griffin2, Ailing Lu3, Emma Kuan4, Nicholas Moss4, Andrea La Bella5, Allison O'Rourke2, Hayley Waterman2, Erik Layton4, Paige Bouvatte4, Peter Wittig4, Susan Shenoi6, Troy Torgerson4, Carmen Mikacenic2, Cate Speake2, Joyce Hui-Yuen3, Daniel Campbell2, Betsy Barnes3 and Jessica Hamerman2, 1University of Washington, 2Benaroya Research Institute, 3Feinstein Institutes for Medical Research, 4Allen Institute, 5Cohen Children's Medical Center, 6Seattle Children's Hospital and Research Center, Mercer Island, WA

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Friday, March 20, 2026

Title: Plenary Abstract Session II

Session Time: 2:45PM-3:00PM

Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), is a potentially fatal complication of rheumatic diseases, most commonly systemic juvenile idiopathic arthritis (sJIA) or Still’s disease. MAS is driven by aberrant activation of lymphocytes and phagocytes with an important role for interferon gamma (IFNg). While monocytes and macrophages are thought to be important in MAS pathogenesis, their role remains poorly understood.

Methods: Subjects with MAS were defined based on the 2016 classification criteria by Ravelli and colleagues as well as the ratio of ferritin to ESR. We analyzed classical CD14+ monocytes from children with active MAS (6 subjects) compared to age/sex/race matched healthy children (8 subjects) by flow cytometry and RNA sequencing (RNA-Seq). Differentially expressed genes (DEGs) were defined as those with at least 2 fold change and false discovery rate less than 0.1. We also analyzed monocytes (n=8 per group) and lymphocytes (n=6 per group) using single cell RNA-Seq. We determined plasma concentrations of specific cytokines using Meso Scale Discovery assays. We used Tensor-cell2cell to determine significantly different interactions between MAS and HC lymphocytes and monocytes.

Results: We identified a cluster of monocytes with evidence of interferon (IFN) stimulation defined by high levels of interferon stimulated genes (ISGs) that was expanded in subjects with MAS compared to HC. Unexpectedly, cluster defining genes in ISGhigh monocytes were driven by type I IFN rather than IFNg by several metrics. Consistent with this finding, we detected increased levels of circulating IFNb in MAS subjects. We also found significant upregulation of CD16 surface expression during active MAS and showed that IFNb increased CD16 transcript, together suggesting that IFNb could play a previously unrecognized role in driving MAS monocytes responses. Using bulk RNA-Seq of CD14+ classical monocytes, we identified a MAS signature score that correlated with ferritin, a laboratory marker of hyperinflammation. This MAS signature score was higher in children with active sJIA than during inactive disease and higher in children with MAS than in sJIA without MAS. We also found that this signature score was elevated in monocytes from children with lupus where it correlated with disease activity and from adults with severe COVID-19, highlighting its utility across different inflammatory triggers. We identified a MAS-associated CD8+ T cell population defined by increased expression of multiple inhibitor receptors highly expressed by chronically activated T cells, including HAVCR2, LAG3, and CTLA4, in addition to CD27, which is typically expressed on proliferating T cells. Cell-cell interaction analyses revealed significantly enhanced immunoregulatory interactions between monocytes and T cells during MAS.

Conclusion: Together, these results provide new evidence for a role for IFNb during MAS, identify a signature score associated with disease severity in several inflammatory diseases, and identify a unique CD8+ T cell population that may contribute to MAS pathophysiology.


Disclosures: S. Canny: Sobi, 1; H. DeBerg: None; G. Griffin: None; A. Lu: None; E. Kuan: None; N. Moss: None; A. La Bella: None; A. O'Rourke: Mozart Therapeutics, 3; H. Waterman: None; E. Layton: None; P. Bouvatte: None; P. Wittig: None; S. Shenoi: Cure JM, 5, Pfizer, 2, 5, sobi, 2; T. Torgerson: None; C. Mikacenic: None; C. Speake: None; J. Hui-Yuen: None; D. Campbell: None; B. Barnes: None; J. Hamerman: None.

To cite this abstract in AMA style:

Canny S, DeBerg H, Griffin G, Lu A, Kuan E, Moss N, La Bella A, O'Rourke A, Waterman H, Layton E, Bouvatte P, Wittig P, Shenoi S, Torgerson T, Mikacenic C, Speake C, Hui-Yuen J, Campbell D, Barnes B, Hamerman J. Expansion of Type I IFN-driven ISGhigh Monocytes and Identification of MAS-Associated CD8+ T cell Population During Macrophage Activation Syndrome [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/expansion-of-type-i-ifn-driven-isghigh-monocytes-and-identification-of-mas-associated-cd8-t-cell-population-during-macrophage-activation-syndrome/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-type-i-ifn-driven-isghigh-monocytes-and-identification-of-mas-associated-cd8-t-cell-population-during-macrophage-activation-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology